ArticleFrontiers in medicine2025
Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.American journal of clinical dermatology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alopecia areata (AA) is a common autoimmune hair loss disorder with a highly variable course and substantial psychosocial impact. Evidence from long-term prospective cohorts remains limited. To characterize the natural history, treatment outcomes, relapse patterns, quality-of-life changes, and safety profile of AA over 52 weeks in a real-world clinical setting. Methods: In this single-center prospective cohort, 400 patients with AA and 80 healthy controls were followed for 52 weeks, with assessments at weeks 4, 12, 24, 36, and 52. Disease severity was quantified using the Severity of Alopecia Tool (SALT). Primary outcomes included SALT50 and SALT90 achievement at week 24; secondary outcomes were relapse at week 52, patient-reported outcomes [Dermatology Life Quality Index (DLQI), Skindex-16, itch/pain numeric rating scale (NRS)], and safety. An imaging subcohort ( Results: By week 52, 31.8% of patients relapsed, with a median relapse time of 28 weeks. SALT improved over time, with mean scores declining from 38.6 ± 21.7 at baseline to 22.4 ± 17.1 at week 52 ( Conclusion: This prospective cohort provides longitudinal evidence that baseline severity, disease activity, and relapse history are major determinants of response and recurrence in AA. Standardized severity scores, patient-reported outcomes, and imaging biomarkers may improve risk stratification, personalized care, and real-world evaluation of current therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.